Related content

Phase II Study of Gemcitabine, UFT and Leucovorin in Patients with Advanced Pancreatic Cancer

By Kim Tae Won   Kang Hae Jin   Ahn Jin Hee   Lee Keehyun   Chang Heung Moon   Kang Yoon Koo   Lee Jung Shin  

Acta Oncologica, Vol. 41, Iss. 7-8, 2002-11 ,pp. : 689-694

Informa Healthcare

Access to resources Recommend Favorite

Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer

By                    

Experimental and Therapeutic Medicine, Vol. 2, Iss. 1, 2011-01 ,pp. : 109-117

Spandidos Publications

Access to resources Recommend Favorite

Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens

By  

International Journal of Oncology, Vol. 46, Iss. 1, 2015-01 ,pp. : 55-62

Spandidos Publications

Access to resources Recommend Favorite

Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

By Svane Inge   Pedersen Anders   Johnsen Hans   Nielsen Dorte   Kamby Claus   Gaarsdal Eva   Nikolajsen Kirsten   Buus Søren   Claesson Mogens  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 633-641

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study - docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

By Rougier P.   Adenis A.   Ducreux M.   de Forni M.   Bonneterre J.   Dembak M.   Clouet P.   Lebecq A.   Baille P.   Lefresne-Soulas F.   Blanc C.   Armand J.P.  

European Journal of Cancer, Vol. 36, Iss. 8, 2000-05 ,pp. : 1016-1025

Elsevier

Access to resources Recommend Favorite